The WHO R&D Blueprint is a programme launched in 2016 to accelerate vaccine and treatment development for high-risk pathogens including Ebola, Marburg, Lassa, Nipah, MERS-CoV and Disease X.

What are the three WHO pathogen roadmaps published in early 2026?

WHO published a Filovirus roadmap on 3 March, an Arenaviridae roadmap on 12 March, and a Paramyxovirus roadmap on 31 March 2026. Public consultations on all three remain open through late May.Source: WHO R&D Blueprint

What is Disease X on the WHO priority pathogen list?

Disease X is a deliberate placeholder on the WHO R&D Blueprint priority list for an as-yet-unknown pathogen with pandemic potential, used to prompt investment in flexible platform technologies rather than pathogen-specific vaccines.

Background

The WHO R&D Blueprint is a WHO programme launched in 2016 following the Ebola crisis, designed to accelerate research and development of medical countermeasures (vaccines, diagnostics, therapeutics) for pathogens that pose pandemic or epidemic risk. The Blueprint maintains the official WHO priority pathogen list, which identifies diseases for which no or insufficient medical countermeasures exist and for which investment is urgently needed. Pathogens on the current list include Ebola, Marburg, Lassa, Nipah, Hendra, Crimean-Congo haemorrhagic fever, Rift Valley fever, MERS-CoV, SARS-CoV, and Disease X (a placeholder for an unknown future pandemic pathogen). The Blueprint coordinates with CEPI, BARDA, Wellcome, and national research funders to sequence R&D investment against these threats.

In Q1 2026 the WHO R&D Blueprint published three pathogen-family medical countermeasure roadmaps: the Filovirus roadmap on 3 March (covering Ebola and Marburg), the Arenaviridae roadmap on 12 March (covering Lassa, Junin and related haemorrhagic fevers), and the Paramyxovirus roadmap on 31 March (covering Nipah, Hendra and measles). The Filovirus roadmap explicitly named non-Zaire Ebola species, including Bundibugyo, as a research-priority gap, three months before the 17 May PHEIC declaration made that gap a live operational problem with no approved MCMs available.

Africa CDC and WHO are now pointing to the Blueprint Filovirus roadmap in Bundibugyo coordination calls as the justification for accelerated R&D investment in non-Zaire species. The roadmap is also the priority-pathogen layer feeding CEPI's 100 Days Mission target, the ambition to develop a SAFE, efficacious vaccine within 100 days of a pathogen of pandemic potential being identified. Bundibugyo's appearance on the roadmap pre-outbreak means CEPI's candidate-selection framework was already nominally positioned, even as no candidate was in clinical trials when outbreak was declared.

That diagnostic gap narrowed on 2 July 2026, when WHO added the first molecular diagnostic for Bundibugyo virus to its Emergency Use Listing, as testing capacity across the ten DRC/Uganda laboratories serving the outbreak rose from 200-400 to over 2,000 tests a day. The gap the Filovirus roadmap flagged pre-outbreak remains only partly closed: no vaccine or treatment for the species carries full licensure, and the diagnostic listing addresses detection capacity rather than the therapeutic shortfall.